La vendita allo scoperto per Vend Marketplaces dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Vend Marketplaces. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Vend Marketplaces (OTC:SBBTF) Azioni, Report sulle vendite allo scoperto

Vend Marketplaces ASA, formerly Schibsted ASA is a Norway-based multimedia group that owns and operates newspapers, online classified advertisement websites, publishing houses, and other multimedia services. The company's majority sources of revenue are its Norwegian and Swedish newspapers and tabloid magazines such as Verdens Gang, Aftenposten, and Aftonbladet. It also operates other regional magazines, classified websites, and local newspapers in over 25 different countries around Europe, Asia, Latin America, and Africa. Schibsted's newspaper operations outside of Scandinavia are based in Spain and France.

VEND MARKETPLACES ASA B by VEND MARKETPLACES ASA

Vend Marketplaces ASA

Citigroup analyst Andrew Kaplowitz maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Buy and raises the price target from $709 to $831.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Parker Hannifin, Raises Price Target to $831

Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares are trading higher Monday on possible continued momentum after Secretary of Defense Pete Hegseth announced efforts to fast <a href="https://www.benzinga.com/node/46372724">track drone production.</a>
What To Know: On Thursday, Hegseth issued a directive allowing military commanders at the rank of colonel or Navy captain and above to independently purchase and test small drones—specifically Group 1 and 2 unmanned aircraft systems.
Furthermore, the order reclassifies these drones as "consumable weapons," removing them from traditional aircraft tracking systems and accelerating the deployment of emerging tech, including 3D-printed and off-the-shelf models.
The directive also rolls back several outdated Pentagon policies that Hegseth said were stalling innovation. It requires all military branches to conduct drone combat simulations and coordinate with the FAA to expand flight ranges, fast-track spectrum approvals and create new testing zones for swarm tactics, live-fire drills and joint-force exercises.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46399600/nebius-emerges-as-neutral-ai-cloud-alternative-deepens-ties-with-nvidia-openai-microsoft-analyst">Nebius Emerges As Neutral AI Cloud Alternative, Deepens Ties With Nvidia, OpenAI, Microsoft: Analyst</a>
RCAT Price Action: At the time of writing, Red Cat stock is trading 15.7% higher at $9.91, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image via Shutterstock

Movers

RCAT

Red Cat Stock Is Moving Higher Monday: What's Going On?

Citigroup analyst Vladimir Bystricky maintains nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) with a Buy and raises the price target from $69 to $86.

Citigroup Maintains Buy on nVent Electric, Raises Price Target to $86

<a href="https://www.bloomberg.com/news/articles/2025-07-14/us-bank-regulators-provide-blueprint-for-lenders-crypto-custody">https://www.bloomberg.com/news/articles/2025-07-14/us-bank-regulators-provide-blueprint-for-lenders-crypto-custody</a>

General

'US Bank Regulators Provide Blueprint for Lenders' Crypto Custody'- Bloomberg

Citigroup analyst Andrew Kaplowitz maintains Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) with a Buy and raises the price target from $23 to $24.

Citigroup Maintains Buy on Mirion Technologies, Raises Price Target to $24

Citigroup analyst Andrew Kaplowitz maintains Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) with a Buy and raises the price target from $17 to $21.

Citigroup Maintains Buy on Mayville Engineering, Raises Price Target to $21

Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) on Monday announced it has added another 4,225 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to its already dominant crypto treasury, spending approximately $472.5 million at an <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46397477/bitcoins-123k-boom-meets-crypto-week-blastoff-moment-for-microstrategy-marathon-digital">average price of $111,827 per coin</a>.
The purchase was disclosed Monday morning in a Form 8-K <a href="https://assets.contentstack.io/v3/assets/bltf8d808d9b8cebd37/blt4cc1a0ae496ac9e3/68747439e8921d53d6fa6b41/form-8-k_07-14-2025.pdf">filing</a> with the U.S. Securities and Exchange Commission.
The acquisition pushes Strategy's total holdings to 601,550 BTC, acquired for roughly $42.87 billion at an average price of $71,268 per Bitcoin. 
The announcement comes amid Bitcoin's recent surge past $122,000, underscoring Strategy's aggressive buy-the-dip approach that now spans across more than three years and multiple bull-bear cycles.
What makes this purchase noteworthy isn't just the size, but the source of the funds: Strategy financed the latest acquisition using proceeds from four concurrent at-the-market (ATM) equity offerings, including its common stock and three series of preferred shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRK#NASDAQ">STRK</a>), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>) and (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRD#NASDAQ">STRD</a>).
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46394828/bitcoin-eth-xrp-solana-are-in-for-a-long-and-exhausting-bull-market-bernstein-predicts">Bitcoin, ETH, XRP, Solana Are In For A &#8216;Long And Exhausting Bull Market,&#8217; Bernstein Predicts</a>
Over the same week, the company raised more than $472 million through those offerings, converting equity capital directly into Bitcoin with little delay.
The company's strategy, blending traditional capital markets with direct Bitcoin accumulation, continues to test conventional corporate treasury management. 
While the firm has become a proxy for institutional Bitcoin exposure on Wall Street, its risk posture remains polarizing. 
Critics warn of overexposure and limited liquidity, while supporters view the firm as an early archetype for how public companies can integrate digital assets into their balance sheets at scale.
Strategy's public dashboard indicates the company has now purchased more than 13,000 BTC in July alone, suggesting that the current accumulation cycle is far from over, even as Bitcoin trades at all-time highs.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46392541/how-donald-trumps-big-beautiful-bill-was-a-big-beautiful-boost-for-bitcoin">How Donald Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Was A &#8216;Big Beautiful Boost&#8217; For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

STRD

STRF

STRK

Strategy Adds $472 Million In Bitcoin, Ups Total Holdings To Over 600,000 BTC

Citigroup analyst Andrew Kaplowitz maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Neutral and raises the price target from $94 to $110.

Citigroup Maintains Neutral on Johnson Controls Intl, Raises Price Target to $110

As silver prices reach levels not seen in <a href="https://www.benzinga.com/markets/market-summary/25/07/46374536/wall-street-today-trump-eu-tariffs-gold-rallies-silver-bitcoin" target="_blank" rel="noopener">almost 14 years</a>, investors are not only stocking up on bars, but they&#8217;re also loading up on silver ETFs at a record pace. And the game is no longer about price momentum. Structural changes in demand, constricting physical supply, and gold&#8217;s rapidly unaffordable glamour are pointing capital toward <a href="https://www.benzinga.com/etfs">ETFs linked to silver</a>, the &#8220;poor man&#8217;s gold&#8221; that&#8217;s now enjoying a rich run.
Silver ETFs added more than 2,570 tons of the metal since February, Bloomberg data shows, and they are playing a central role in the most recent supply squeeze. The effect has been so sharp that it&#8217;s now tightening the physical silver market in London, the main vaulting center for ETF holdings, and driving borrowing rates for the metal to more than 6%, an astonishing spike from their typical near-zero level.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/07/46305133/central-banks-provide-gold-tailwinds-silver-gains-traction-platinum-pauses">Central Banks Provide Gold Tailwinds, Silver Gains Traction, Platinum Pauses</a>
<h2 class="wp-block-heading">ETF Buyers At The Forefront</h2>
While <a href="https://www.benzinga.com/topic/silver">physical silver markets </a>are constrained, silver ETFs are the investment of choice for both retail and institutional investors seeking to enjoy the rally. Let&#8217;s see how the top players compare:
iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>)
The heavy hitter in the silver ETF space, SLV, holds over 474 million ounces of silver and manages nearly $18 billion in assets under management (AUM). It follows the price of silver by maintaining physical bullion in vaults, providing a low-friction means to get exposure without the hassles of storage.
Why it matters: The largest and most liquid silver ETF, SLV, frequently serves as a barometer of investor sentiment towards the metal. The fund is up almost 30% this year so far.
Aberdeen Standard Physical Silver Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIVR#NYSE">SIVR</a>)
SIVR follows essentially the same approach as SLV, owning fully allocated physical silver, but draws more budget-price-conscious investors. At an expense ratio of 0.30%, versus SLV&#8217;s 0.50%, it has slowly gained a niche.
Why it&#8217;s important: Lower costs become more appealing in a high-inflation world where even slight differences in interest rates matter. Like SLV, the fund is up 30% so far this year.
Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>)
Those who want silver exposure but prefer the equity approach can achieve it via SIL, which offers access to a portfolio of international silver mining firms, including Fresnillo (OTCPK: FNLPF), Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>), and Hecla Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>).
Why it matters: Although mining stocks provide leverage to silver prices, they also carry company-specific and geopolitical risks. SIL is rising sharply this year as silver miners benefit from the bull run. The fund is up a good 53.5% this year.
<h2 class="wp-block-heading">What&#8217;s Driving The Demand?</h2>
A variety of forces are driving investor demand:
Relative value: Silver remains trading below its historic ratio to gold. At an 86 gold-to-silver ratio, silver could be undervalued, given that the number averages nearer to 80 over the past decade.
Trade tensions: The most recent round of threats of tariffs between the U.S. and Mexico, the globe&#8217;s leading silver producer, raised concerns about potential supply interruptions.
Industrial demand: Silver is an essential input for solar panels and electronics, making it have a special dual identity, both a precious metal and an industrial commodity.
Supply deficit: The Silver Institute estimates a fifth straight year of market deficit in 2025, as cited by Bloomberg, further solidifying the long-term investment thesis.
<h2 class="wp-block-heading">The Bigger Picture For ETF Flows</h2>
This year&#8217;s rally has transformed silver ETFs from quiet portfolio diversifiers into high-conviction trades. While gold ETFs have mostly recorded flat to negative inflows due to high prices and risk-off central bank sentiment, silver ETFs are attracting new money, courtesy of their lower entry price and more compelling upside story.
If silver continues to outpace gold, as it has to date in 2025, the pace of ETF flows will gain even more momentum, particularly for retail investors seeking exposure without exceeding their budgets.
Silver does not have the bling of gold, perhaps, but in the world of ETFs, it&#8217;s stealing the spotlight right now. Tightening physical supply and increasing investor appetite have turned silver ETFs from supporting actors to protagonists in the commodity resurrection.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46398559/are-your-tesla-etfs-secretly-betting-on-elon-musks-ai-startup">Are Your Tesla ETFs Secretly Betting On Elon Musk's AI Startup?</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

ETFs

FNLPF

PAAS

SIVR

Silver ETFs Just Crashed Gold's Party— And Took The Cake

Citigroup analyst Vladimir Bystricky maintains ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) with a Buy and raises the price target from $159 to $186.

Citigroup Maintains Buy on ITT, Raises Price Target to $186

Crinetics Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) on Sunday announced new data from its clinical development program evaluating once-daily, oral investigational palsonify (paltusotine) <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in acromegaly</a>.
Acromegaly&nbsp;is a rare condition in adults that causes some bones, organs and other tissues to grow bigger.
The data will be presented at the Endocrine Society&#8217;s Annual Meeting, ENDO 2025.
Also Read: <a href="https://www.benzinga.com/25/03/44502320/jp-morgan-survey-90-of-endocrinologists-aware-of-crinetics-atumelnant-data" target="_blank" rel="noreferrer noopener">JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics&#8217; Atumelnant Data</a>
<h2 class="wp-block-heading">PATHFNDR-1 Open-Label Extension (OLE) Study</h2>
The PATHFNDR-1 Phase 3 trial enrolled adults with acromegaly who were biochemically controlled on monthly injectable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46383977/crinetics-to-present-new-long-term-data-demonstrating-durable-control-of-once-daily-oral-palsonify" rel="noreferrer noopener">somatostatin receptor ligands (SRLs)</a>.
Following a 36-week randomized, placebo-controlled period, 53 of 58 participants (91%) entered the ongoing single-arm open-label extension. An interim analysis includes data through week 96 of total study participation (60 weeks in the OLE).
In patients who transitioned from injected SRLs to once-daily oral palsonify, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and 0.81 ± 0.21 times the upper limit of normal (ULN) at week 96, demonstrating durable biochemical control over this period.
Growth hormone (GH) levels were also stable, with mean values of 1.0 ± 1.0 ng/mL at baseline and 1.1 ± 1.2 ng/mL at week 96.
Symptom control also remained stable at week 96.
<h2 class="wp-block-heading">PATHFNDR-2 OLE Study</h2>
The interim analysis includes efficacy data from 88 patients through week 84 (corresponding to 60 weeks in the OLE), with safety data reported for all 114 enrolled.
Patients who had received a placebo during the RC phase experienced sustained reductions in IGF-1, with a mean change from baseline of –0.81 × ULN at week 84 (n=39).
Direct-to-OLE participants (n=9) showed similar reductions (–0.75 × ULN), while those who had been treated with palsonify during the RC phase (n=40) maintained control (mean change –0.01 × ULN).
Growth hormone, symptom scores, and pituitary tumor size were durably controlled over the study period.
In both trials, palsonify was well-tolerated.
A pooled analysis of symptom scores from PATHFNDR-1 and PATHFNDR-2 showed that greater proportions of patients treated with palsonify experienced less acromegaly symptom burden compared to placebo, regardless of the magnitude of the symptom effect, treatment history or state of biochemical disease control.
In an analysis of PATHFNDR-1 data, biochemically controlled patients switching from injected SRLs to palsonify saw a significant drop in day-to-day symptom exacerbations, from over 30% of days on SRLs to just 6.2% during stable palsonify dosing.
CRNX Price Action: Crinetics Pharmaceuticals stock is up 3.07% at $32.91 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46386533/dave-ramsey-warns-bankruptcy-is-huge-red-flag-that-can-delay-homeownership-by-years" target="_blank" rel="noreferrer noopener">Dave Ramsey Warns Bankruptcy Is &#8216;Huge Red Flag&#8217; That Can Delay Homeownership By Years</a></li>
</ul>
Photo: Gorodenkoff via Shutterstock

Biotech

Health Care

CRNX

Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) from Outperform to Market Perform.

Downgrades

INKT

William Blair Downgrades MiNK Therapeutics to Market Perform

Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). 
The drug targets post-bariatric hypoglycemia (PBH), a condition marked by dangerously low blood sugar following weight-loss surgery.
In the Phase 2b trial, a 90 mg once-daily dose of avexitide—now being evaluated in the Phase 3 LUCIDITY trial—achieved a 64% reduction in the rate of moderate to severe hypoglycemic events. More than half of participants experienced no such events during treatment.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46081532/amylyx-eyes-2b-opportunity-in-post-surgery-sugar-crash-market" target="_blank" rel="noreferrer noopener">Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market</a>
LUCIDITY, a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial, is evaluating the safety and efficacy of avexitide in approximately 75 patients with PBH following Roux-en-Y gastric bypass surgery. The FDA-designated primary endpoint is a reduction in Level 2 and 3 hypoglycemic events.
Previous trials, including Phase 2 PREVENT and Phase 2b, showed consistent, dose-dependent reductions in these events across multiple dosing regimens. Notably, the 90 mg once-daily dose demonstrated sustained 24-hour GLP-1 receptor inhibition, supported by pharmacokinetic and pharmacodynamic data presented at ENDO 2025. In vitro studies confirmed potent target engagement, with avexitide plasma levels exceeding the IC₅₀ threshold throughout the dosing window.
Across five clinical trials, avexitide has shown statistically and clinically meaningful efficacy with a favorable safety profile. LUCIDITY is expected to complete enrollment in 2025, with top-line results anticipated in the first half of 2026 and a potential commercial launch in 2027.
Price Action: AMLX stock is up 7.55% at $8.26 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surged-nearly-50-in-2025" target="_blank" rel="noreferrer noopener">Stanley Druckenmiller&#8217;s Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Image: Shutterstock

Trading Ideas

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Citigroup analyst Andrew Kaplowitz maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Buy and raises the price target from $91 to $104.

Citigroup Maintains Buy on Ingersoll Rand, Raises Price Target to $104

Pudgy Penguins (CRYPTO: PENGU) has surged more than 90% in a week as bullish momentum builds around strong fundamentals, brand utility, <a href="https://www.benzinga.com/25/04/45046221/pudgy-penguins-coin-pengu-outperforms-dogecoin-shiba-inu-with-123-weekly-gain">and regulatory developments.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Pudgy Penguins</td>
<td>(CRYPTO: PENGU)</td>
<td>$0.02837</td>
<td>&nbsp;$1.78 billion</td>
<td>+94%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2003</td>
<td>&nbsp;$30.07 billion</td>
<td>+19.3%</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001343</td>
<td>&nbsp;$7.91 billion</td>
<td>+16.1%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1944731100787417261">said</a> PENGU is showing leadership in the meme coin sector, currently riding anuptrend on the daily chart. 
The token is approaching a retest of its previous all-time highs, and a breakout could occur soon. 
With strong mainstream (&#8220;normie&#8221;) appeal and having launched during a meme bear market, it has yet to experience true price discovery.
Crypto chart analyst Ali Marinez <a href="https://x.com/ali_charts/status/1944539085378330924">drew</a> parallels between PENGU and PEPE but emphasized a key differentiator: PENGU has real-world traction. 
Backed by a brand with over $13 million in toy sales at Walmart and Target, Pudgy Penguins boasts strong IP, a growing ecosystem, and royalty-sharing for NFT holders.
With a spot ETF now filed, PENGU looks fundamentally strong and still early in its growth cycle.
Degengambleeh <a href="https://x.com/degengambleh/status/1944698902709465542">added</a> that PENGU's reclaim of key resistance levels isn't just a bullish sign for holders, but a signal for the broader crypto space. 
With clear skies until $0.05, PENGU could represent the next phase of meme-driven adoption powered by narrative, culture, and utility.
Statistics: Pudgy Penguins NFT <a href="https://nftpricefloor.com/pudgy-penguins">reported</a> an expansion of 15.5% in its volume and 3.1% growth in sales. The average sale grew 12%. The price of Pudgy Penguin NFTs spiked from 9 ETH to 11.58 ETH in a week.
The price spike coincided with Coinbase <a href="https://x.com/coinbase/status/1943715559209590821?ref_src=twsrc%5Etfw">changing</a> its X profile picture to a Pudgy Penguin NFT, posting "new pfp, who dis." Other firms including VanEck, MoonPay, and AwakenTax followed suit, reinforcing community strength and meme power.
Community News: The SEC has acknowledged Canary Capital's filing for the Canary PENGU ETF. 
On July 9, the Cboe BZX Exchange submitted a proposal to list and trade shares of the fund, bringing PENGU one step closer to becoming the first meme coin ETF built around an NFT-native brand.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/07/46315623/anthony-scaramucci-once-slammed-dogecoin-other-memecoins-as-distraction-from-the-purity-of-bitcoin-this-is-the-stuff-that-would-aggravate-warren-buffett">Anthony Scaramucci Once Slammed Dogecoin, Other Memecoins As &#8216;Distraction&#8217; From The Purity Of Bitcoin — This Is The Stuff That Would Aggravate Warren Buffett</a></li>
</ul>
Image: Shutterstock

$DOGE

$SHIB

Pudgy Penguins Coin PENGU Leaps Past Dogecoin, Shiba Inu, Pepe With 93% Weekly Gain

Citigroup analyst Andrew Kaplowitz maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Neutral and raises the price target from $254 to $265.

Citigroup Maintains Neutral on Illinois Tool Works, Raises Price Target to $265

As the tech industry increasingly pivots towards artificial intelligence, Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is positioning itself at the forefront of this shift with its AI-powered Service Cloud. This strategic move not only highlights the growing <a href="https://www.benzinga.com/topic/artificial-intelligence">importance of AI</a> in driving business growth but also reshapes investor perceptions of Salesforce&#8217;s long-term potential.
Bank of America Securities analyst Brad Sills <a href="https://www.benzinga.com/quote/CRM/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Buy</a> rating on Salesforce with a price target of $350 on Monday.
Salesforce is betting big on its largest business unit, Service Cloud, which analysts expect will generate $9.7 billion in fiscal 2026 revenue, making up 25% of total subscription revenue, Sills noted. In the first quarter of fiscal 2026, growth slowed slightly to 7%.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46393365/salesforce-underperforms-market-as-growth-concerns-plague-crm-giant" target="_blank" rel="noreferrer noopener">Salesforce Underperforms Market As Growth Concerns Plague CRM Giant</a>
Still, after adjusting for leap year effects and rounding, the analyst noted that the normalized rate stands closer to 8.5%, indicating only a modest deceleration.
He noted the slowdown has bottomed out and projects acceleration to 9% in the coming quarters, trending toward 12% in the long run.
Sills noted that Service Cloud's growth potential stands out across the industry, with projected incremental gains of 21%, significantly ahead of the next closest competitor at 7%. The analyst attributed this outperformance to Service Cloud's user-friendly interface, deep customization, seamless integration across sales and service, and, most notably, Agentforce, Salesforce's AI-powered service agent suite.
He said that add-ons such as Service Cloud Voice, Field Service, Customer Experience Intelligence, and Digital Engagement represent durable upsell opportunities that support this bullish outlook.
Sills noted that Salesforce's Agentforce AI suite is becoming a central growth lever. In recent partner conversations, the analyst stated that use cases such as case management, meeting preparation, shipment tracking, and analytics were repeatedly cited. 
He expects Agentforce for Service Cloud to contribute $1.7 billion in revenue over the next five years, helping the platform achieve a compound annual growth rate (CAGR) of 9%, or 12% in an upside scenario. Sills noted that over 8,000 customers have already signed up for AI agents, with more than half of them converting to paying accounts.
The analyst noted that the Service Cloud platform provides agents with powerful tools, including AI-driven case routing, knowledge base searches, and self-service customer portals, making it a key enabler of customer satisfaction and lifetime value.
Salesforce offers pricing tiers ranging from the $25/month Starter Suite to the $550/month Agentforce 1 edition, which bundles AI credits and Data Cloud capacity for enterprise-scale deployments. According to the analyst, this flexible pricing model facilitates broad adoption across businesses of all sizes.
Crucially, Salesforce's go-to-market strategy integrates Agentforce into its existing customer base—60% of which already uses Sales or Service Cloud—allowing for easy cross-sell and bundled offerings, Sills noted. He said that by publicizing case studies from OpenTable, PepsiCo, and other enterprise users, Salesforce aims to demonstrate real-world benefits and drive deeper adoption of Agentforce.
The analyst noted that Salesforce is well-positioned to reaccelerate top-line growth with its AI-first vision, full-stack capabilities, and established customer base. He added that Service Cloud's continued evolution, primarily through Agentforce, may very well be the company's ticket to sustained leadership in enterprise software through the end of the decade.
Sills projected fiscal 2026 sales of $41.2 billion and EPS of $11.28.
CRM Price Action: Salesforce shares were up 1.07% at $260.83 at the time of publication Monday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46387027/alibaba-bleeds-billions-as-delivery-price-war-erases-100-billion-in-market-value" target="_blank" rel="noreferrer noopener">Alibaba Bleeds Billions As Delivery Price War Erases $100 Billion In Market Value</a></li>
</ul>
Photo: Shutterstock

Reiteration

Salesforce's AI Moves Could Skyrocket Service Cloud Revenue

TROO

TROOPS Shares Halted On Circuit Breaker To The Upside, Stock Now Up 247.7%

WIIM

VIOT

Viomi Technology shares are trading higher after the company announced its board has approved a special dividend of $0.0293 per share.

Citigroup analyst Vladimir Bystricky maintains IDEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) with a Buy and raises the price target from $208 to $216.

Comments

Vend Marketplaces

Vendite allo scoperto

Vend Marketplaces (OTC:SBBTF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO